Sylvester Comprehensive Cancer Center

  • 20210835 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:

    IRB: 20210835

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: BEIGENE

    Enrolling Sites:

    Gables
    Sylvester

    Title:

    A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

    Eligibility Criteria - NCT04973605 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220421 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20220421

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Janssen

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 3 Randomized Study Comparing Bortezomib, enalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd)

    Eligibility Criteria - NCT04923893 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220595 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:

    IRB: 20220595

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

    Eligibility Criteria - NCT05530421 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220955 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:

    IRB: 20220955

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: ABBVIE

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

    Eligibility Criteria - NCT05259839 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221315 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:

    IRB: 20221315

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Ichnos Sciences SA

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

    Eligibility Criteria - NCT05427812 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201316 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20201316

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Moffitt Cancer Center
    Plantation
    Sylvester
    UMH

    Title:

    Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

    Eligibility Criteria - NCT04268498 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201536 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20201536

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications

    Eligibility Criteria - NCT04814615 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210341 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20210341

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: PFIZER

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    MagnetisMM-4 A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

    Eligibility Criteria - NCT05090566 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220203 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20220203

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma

    Eligibility Criteria - NCT05308654 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221148 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20221148

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    Teclistamab or Talquetamab in Combination with Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Sequential Cohort Immuno-oncology Study to REVIVE Early Myeloma

    Eligibility Criteria - NCT06100237 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230160 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20230160

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Janssen

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With

    Eligibility Criteria - NCT05455320 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230227 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20230227

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients with Relapsed/Refractory Multiple Myeloma

    Eligibility Criteria - NCT05896228 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230479 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20230479

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: PFIZER

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTO

    Eligibility Criteria - NCT05020236 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230685 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20230685

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

    Eligibility Criteria - NCT05675449 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230969 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20230969

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Janssen

    Enrolling Sites:

    Gables
    Sylvester
    UMH

    Title:

    A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther

    Eligibility Criteria - NCT05572515 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231309 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20231309

    SDG: Multiple Myeloma
    Disease Site(s):

    Multiple

    Sponsor: Janssen

    Enrolling Sites:

    Gables
    Sylvester
    UMH

    Title:

    A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

    Eligibility Criteria - NCT05438043 *This information has been extracted from " www.clinicaltrials.gov"